A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Inclusion Criteria:
Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
Part 1: Have received prior CLL/SLL treatment
Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
Have received a covalent BTK inhibitor
Part 2: Have received no prior treatment for CLL/SLL
Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy
Capable of swallowing oral study medication.
Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.
Exclusion Criteria:
Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor
Have known or suspected Richter's transformation
Have known or suspected history of central nervous system involvement by CLL/SLL
Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Chandler, Arizona 85224, United States
Palo Alto, California 94304, United States
Miami, Florida 33136, United States
Newnan, Georgia 30265, United States
Mulhouse, 68100, France
Tours, 37044 Cedex 9, France
Αthens, 11526, Greece
Roma, 00168, Italy
Wroclaw, 50-367, Poland
Banská Bystrica, 975 17, Slovakia
Hwasun-gun, 58128, South Korea
L'Hospitalet Del Llobregat, 08908, Spain
Salamanca, 37007, Spain
Ankara, 06200, Turkey (Türkiye)
800-826-4673
626-218-2405
303-418-7639
515-282-2921
301-571-2016
228-575-1234
252-744-1015
541-683-5001
717-741-9229
901-683-0055
512-421-4100
999-999-9999
757-368-0437
61 3 6166 6655
0240143021
3250452320
+32 9 332 21 25
003251237322
087219418
0042053233562
+420495832886
+420606901110
+420224966845
+33255463467
00496956005621
0049551488795915
004989979680
0049 60214527391
49 261 921 5693-0
+302107201721
0030 2105832307
+302313307533
36208258660
+3630 455 8218
+36 72 536 000
+36704391136
0805593471
+390532236977
00390557947958
+39 03213733880
0498217809
+390916802773
+390755783990
0649974773
+39 0630157833
+4832 3499751
+48 602338290
501419272
40212750500
0744150652
400741337480
0735439439
40722565781
0724877013
+421915803313
+421556404410
421902101385
+821089371258
82222586056
+821042324067
+34 93 274 61 00 EXT 3806
932275400
911918932
34913368637
91 191 69 71
+34951976957
985108000
34923291100
34942315321
3495049697
34 955013277
00905326560206
905325566128
05076771924
111111111
0141 301 7711
02088692742
01132433144
07833432491
017920285547